CStone Pharmaceuticals (HKSE:02616) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is CStone Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CStone Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Jun. 2023 was 0.00.

CStone Pharmaceuticals's long-term debt to total assets ratio declined from Jun. 2022 (0.08) to Jun. 2023 (0.00). It may suggest that CStone Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

CStone Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for CStone Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CStone Pharmaceuticals LT-Debt-to-Total-Asset Chart

CStone Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.06

0.15

0.14

CStone Pharmaceuticals Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial									0.06	0.08	0.15	-	0.14

CStone Pharmaceuticals LT-Debt-to-Total-Asset Calculation

CStone Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	245.154	/	1817.859
	=	0.13

CStone Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (Q: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2023 )	/	Total Assets (Q: Jun. 2023 )
	=	0	/	0
	=

CStone Pharmaceuticals (HKSE:02616) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CStone Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of CStone Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

CStone Pharmaceuticals (HKSE:02616) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (HKSE:02616) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

CSPHF:USA PH4:Germany

Address

218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123

Website

https://www.cstonepharma.com

CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.

Executives

Su Zhou Gong Ye Yuan Qu Zheng Ze Yuan Shi Chuang Ye Tou Zi Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Gong Ye Yuan Qu Zheng Ze Ji Ming Gu Quan Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Zheng Ze Jian Kang Chuang Ye Tou Zi Guan Li Zhong Xin You Xian He Huo	2501 Other
Su Zhou Gong Ye Yuan Qu Yuan He Yuan Dian Chuang Ye Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Guan Wei Hui	2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Jing Ji Fa Zhan You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Yuan He Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Fei Jianjiang	2201 Interest of corporation controlled by you
Wuxi Healthcare Ventures Ii, L.p.	2101 Beneficial owner
Wuxi Healthcare Management, Llc	2201 Interest of corporation controlled by you
Morgan Stanley	2201 Interest of corporation controlled by you
Gic Private Limited	2102 Investment manager
Jiang Frank Ningjun	2307 Founder of a discretionary trust who can infl
Graceful Beauty Limited	2101 Beneficial owner
Boyu Capital Holdings Ltd.	2201 Interest of corporation controlled by you

CStone Pharmaceuticals (HKSE:02616) Headlines

No Headlines